Cohance Lifesciences Limited — Updates, 12-08-2025: Press Release

Cohance Lifesciences is investing $10 million in its US subsidiary, NJ Bio, to build a cGMP bioconjugation suite. This strategic expansion significantly enhances their Antibody-Drug Conjugate (ADC) innovation capabilities, allowing integrated solutions from early development to clinical supply. Expected to be operational by Q4FY26, the new facility will support existing innovator programs and secure new customer engagements. This move strengthens Cohance's end-to-end offering in the rapidly growing ADC market, underscoring its focus on advanced, high-potent drug manufacturing for critical therapies.